Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
Latest Information Update: 21 Nov 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2020 Results (data cut off 22 October 2019; n=38) presented at the 2020 Genitourinary Cancers Symposium